Servier's Valdoxan receives EU approval for depression
This article was originally published in Scrip
Executive Summary
The European Commission has granted marketing approval to Servier's Valdoxan (agomelatine) for the treatment of major depressive episodes in adults. It is the first melatonergic antidepressant to be developed. The approval follows a recommendation from the EU's CHMP in November (www.scripnews.com, November 25th, 2008). The company said that it is finalising pricing or individual country launch dates. However, it is aiming to launch in the UK this summer.